UP!

BAX $80.51   View long term graphs

Baxter International Inc.
Type
Public
Traded as NYSE: BAX
S&P 500 Component
Industry Medical equipment
Founded 1931; 86 years ago (1931)
Headquarters Deerfield, Illinois, U.S.
Key people

José E. Almeida, (Chairman & CEO)

Jay Saccaro, (CFO)
Products Medical supplies to treat hemophilia and kidney disease and provide intravenous therapy
Revenue IncreaseUS$10.163B (FY 2016)
Net income
IncreaseUS$4.965B (FY 2016)
Total assets DecreaseUS$15.546B (FY 2016)
Total equity DecreaseUS$8.290B (FY 2016)
Number of employees
48,000 (December 2016)
Website www.baxter.com

José E. Almeida, (Chairman & CEO)

Baxter International Inc. is a Fortune 500 American health care company with headquarters in Deerfield, Illinois. The company primarily focuses on products to treat hemophilia, kidney disease, immune disorders and other chronic and acute medical conditions. The company had 2013 sales of $16.3 billion, across two businesses: BioScience and Medical Products. Baxter's BioScience business produces recombinant and blood plasma proteins to treat hemophilia and other bleeding disorders; plasma-based therapies to treat immune deficiencies and other chronic and acute blood-related conditions; products for regenerative medicine, and vaccines. Baxter's Medical Products business produces intravenous products and other products used in the delivery of fluids and drugs to patients; inhalational anaesthetics; contract manufacturing services; and products to treat end-stage renal disease, or irreversible kidney failure, including products for peritoneal dialysis and hemodialysis.

Baxter International was founded in 1931 by Donald Baxter, a Los Angeles-based medical doctor, as a manufacturer and distributor of intravenous therapy solutions. Seeing a need for products closer to the Midwest, the company opened a manufacturing plant in Glenview, Illinois, in 1933. Baxter's interest was bought out in 1935 by Ralph Falk, who established a research and development function. In 1939 the company developed a vacuum-type collection container, extending the shelf life of blood from hours to weeks. In 1954, the company expanded operations outside of the United States by opening an office in Belgium. In 1956 Baxter International introduced the first functioning artificial kidney, and in 1971 became a member of the Fortune 500.

In 1971, Baxter built a major manufacturing plant in Ashdod, Israel, and as a result, the company was placed on the Arab League boycott list in the early 1980s.

Throughout the 1980s and 1990s the company expanded to deliver a wider variety of products and services (including vaccines, a greater variety of blood products) through acquisitions of various companies. Sales and production facilities also expanded throughout the world.

In 1982, Baxter acquired Medcom, Inc., a New York-based firm founded by Richard Fuisz and his brother, that had large markets in the United States and Saudi Arabia. Baxter chief executive Vernon Loucks fired Fuisz who then brought anti-boycott charges against Baxter to the U.S. Commerce Department Office of Anti-Boycott Compliance (OAC). Fuisz alleged that Baxter had sold their profitable Ashdod facility to Teva Pharmaceutical Industries in 1988 while simultaneously negotiating the construction of a similar plant in Syria in partnership with the Syrian military in order to be removed from the Arab League blacklist in 1989. In 1993 Baxter pleaded guilty to a felony in relation to an anti-boycott law in the United States.

In July 15, 1985, American Hospital Supply Corporation CEO Karl D. Bays and Baxter's then-CEO Vernon R. Loucks Jr. signed an agreement that merged two of the United States' "largest producers of medical supplies". This was a "one-Baxter approach" in which the company provided "70% to 80% of what a hospital needed."

In 1991, Baxter's home infusion subsidiary, Caremark, "was accused by the government of paying doctors to steer patients to its intravenous drug service" In 1992 Caremark spun off from Baxter International. Caremark was fined $160 million for the "four-year-long federal mail-fraud and kickback" scheme in which the "home-infusion business unit made weekly payments to scores of doctors that averaged about $75 per patient for referring those patients to its services. Some doctors earned as much as $80,000 a year from the kickbacks, according to government documents."

In 1996, the company entered into a four-way, $640 million settlement with haemophiliacs 1999 in relation to blood clotting concentrates that were infected with HIV. Under pressure from shareholders due to poor performance and an unsuccessful merger, Loucks was forced to resign.

Baxter acquired medical device firm Baxa on November 10, 2011. In 2011, Hikma Pharmaceuticals PLC completed the acquisition of Baxter Healthcare Corporation's US generic injectables business (Multi-Source Injectables or MSI).

In July 2013, EU antitrust regulators approved Baxter's bid for Sweden's Gambro.

In March 2014, Baxter announced plans to create two separate, independent global health care companies—one focused on developing and marketing bio-pharmaceuticals and the other on medical products. The medical products company retained the name Baxter International Inc. and the bio-pharmaceuticals company is named Baxalta and spun-off as a new public company that showed on trading boards as of July 1, 2015.

In July 2014, Baxter announced that it was exiting the vaccines business—divesting its commercial vaccine portfolio to Pfizer (with sale expected to close by the end of the year) and exploring options for its vaccines R&D program, including influenza. In October 2015, José E. Almeida was named chairman and chief executive officer. In January 2016 Shire PLC agreed to acquire Baxalta for $32 billion.

In December 2016, Baxter announced it would acquire Claris Lifesciences injectables subsidiary, Claris Injectables, for $625 million.

During the tenure of Vernon Loucks, who was Baxter's CEO from 1980 to 1998 and chairman from 1987 to 1999, company sales "more than quadrupled to $5.7 billion while its workforce rose from 30,000 to 42,000." During that time, Loucks hired and groomed a number of staff who went on to become CEOs elsewhere. Baxter alumni groomed by Loucks included Terry Mulligan of MedAssets, Lance Piccolo at Caremark, Mike Mussallem of Edwards Lifesciences Corp and CEOs of Boston Scientific Corp. and Cardinal Health.

In 1997, a report produced by the company indicated that changes made to reduce environmental impacts generated savings that exceeded their cost, producing a net profit. Reporting was company-wide, with a variety of aggregation and reporting, including on the company's internet and intranet sites. The company was an early joiner in the "green and greedy" movement, which aims to lessen the environmental impacts of manufacturing its products while saving the company money. In 2009 the company announced it had reached a variety of its environmentally friendly goals, and that it would continue to try to reduce waste, emissions, energy use and environmental incidents over the coming years.

The company had 2014 sales of $16.7 billion, across two businesses: BioScience (2013 sales - $6.6 billion) and Medical Products ($8.7 billion). Sales in 2013 were 42% in the United States, 30% in Europe, 16% in Asia Pacific, 12% in Latin America and Canada. In 2011, Baxter had approximately 61,500 employees. The breakdown of regional employees in 2013 was 36% in the United States; 34% in Europe; 16% in Asia Pacific; 14% in Latin America and Canada. In 2013, Baxter International spent more than $1.2 billion on research and development.

In 1953 William Graham became the company's CEO. Vernon Loucks became president and CEO in 1980. Loucks was forced to resign by shareholders. When shareholders forced Loucks to resign,

"In January, as Baxter International Inc.'s Vernon Loucks relinquished his CEO duties after 18 years, directors handed him a special stock-option grant of 950,000 shares "for the specific purposes of motivating" him "to implement a smooth transition of his responsibilities." If Mr. Loucks sells all the 400,000 shares he can exercise at year end and Baxter's stock price remains at its current level, he will make more than $4 million."

Loucks was succeeded by Harry Kraemer, who was succeeded by Robert Parkinson, who took the CEO position in 2004.

In June 2009, Baxter International announced it expected to have the first commercial vaccine for the H1N1 ("swine flu") influenza as early as July of the same year. The company has been one of several working with the World Health Organization and United States Centers for Disease Control and Prevention on the vaccine, and uses a cell-based rather than egg-based technology that allows a shorter production time.

In 2008, Baxter launched [email protected]: Expanding Minds with Real-World Science, which supports teacher training and student development in healthcare and biotechnology in Chicago Public Schools.

In 2013, the company was included in The Civic 50, a list of the most community-minded companies in America from The National Conference on Citizenship and Points of Light, published by Bloomberg.

In 2014, roughly 6,300 Baxter employees volunteered in their communities through The Baxter International Foundation's Dollars for Doers program, addressing local concerns such as healthcare, the environment and education. In 2014, Baxter and The Baxter International Foundation gave over $50 million.

Baxter was included for the 13th year in Corporate Responsibility magazine's 100 Best Corporate Citizens list in 2014 for its social responsibility performance.

In August 1975, Baxter / Travenol withdrew a clotting factor product Hemofil after the product was associated with an outbreak of hepatitis B.

Baxter, unknown to the FDA, continued to use prison plasma in factor concentrate production until October 1983, despite having entered into an agreement with the FDA (11 months earlier) that they would no longer use US prison plasma, which posed a high risk of virus transmission.

It was announced in quarter 1 of 1996 that Baxter had agreed to settle a lawsuit involving 200 Japanese haemophilia patients who had become infected with HIV as a result of using contaminated haemophilia products which were unheated. The Japanese courts ordered for each victim to receive $411,460 by March 29 that year.

The Baxter Althane disaster in autumn 2001 was a series of 56 sudden deaths of renal failure patients in Spain, Croatia, Italy, Germany, Taiwan, Colombia and the USA (mainly Nebraska and Texas). All had received hospital treatment with Althane hemodialysis equipment, a product range manufactured by Baxter International, USA.

In 2008, the quality of blood thinning products produced by Baxter was brought into question when they were linked to 19 deaths in the United States. Upon inspection, one of the raw ingredients used by Baxter was found to be contaminated – between 5 and 20 percent – with a substance that was similar, but not identical, to the ingredient itself. The company initiated a voluntary recall, temporarily suspended the manufacture of heparin, and launched an investigation.

Investigation into the contamination has focused on raw heparin produced by Changzhou Scientific Protein Laboratories, a China-based branch of Scientific Protein Laboratories, based in Waunakee, Wisconsin. Due to procedural errors, Changzhou SPL's facilities were never subjected to inspection by US FDA officials, as required by FDA regulations. In addition, Changzhou SPL's products were also never certified as safe for use in pharmaceutical products by Chinese FDA officials, due to Changzhou SPL's registration as a chemical company rather than a pharmaceutical manufacturer. Though Baxter was first to recall heparin because of increased adverse reactions, after the contaminant was identified and testing protocols were shared with other manufacturers globally, over a dozen other companies in nearly a dozen countries issued recalls, which linked back to certain supply points in China.

In early 2009, samples of viral material supplied by Baxter International to a series of European laboratories were found to be contaminated with live Avian flu virus (Influenza A virus subtype H5N1). Samples of the less harmful seasonal flu virus (subtype H3N2) were found to be mixed with the deadly H5N1 strain after a vaccine made from the material killed test animals in a lab in the Czech Republic. Though the serious consequences were avoided by the lab in the Czech Republic, Baxter then claimed the failed controls over the distribution of the virus were 'stringent' and there was 'little chance' of the lethal virus harming humans.

On July 2, 2009, Kentucky Attorney General Jack Conway announced a settlement between the state and Baxter Healthcare Corporation, a subsidiary of Baxter International, worth $2 million. The company had been inflating the cost of the intravenous drugs sold to Kentucky Medicaid, at times as much as 1300%.

In 2010, a jury in Las Vegas, Nevada, ordered Baxter and Teva Pharmaceuticals to pay $144 million to patients who had been infected with hepatitis C after doctors wrongly reused dirty medical supplies to administer propofol to patients, although the label for propofol clearly states that it is for single-patient use only and that aseptic procedures should be used at all times. Per a 2009 indemnity agreement between Teva (the manufacturer) and Baxter (acting as a distributor on behalf of Teva), the litigation and related settlements were defended and paid by Teva.

In 2010, Baxter was ordered by the FDA to recall all of their Colleague infusion pumps from the market due to 87 recalls and deaths associated with the pump.

In December 2011, the non-partisan organization Public Campaign criticized Baxter for spending $10.45 million on lobbying and not paying any taxes during 2008–2010, instead getting $66 million in tax rebates, despite making a profit of $926 million.

News

Baxter International Inc. -3.22% (healthcare)

Q reports

Period Date Adjusted Actuals EPS GAAP EPS
Q4 2020 2021-03-15 Future report Set alerts
Q3 2020 2020-10-22 Future report Set alerts
Q2 2020 2020-07-30 0.64 0.48
Q1 2020 2020-04-30 0.82 0.64
Q4 2019 2020-03-17 0.97 -0.05
Q2 2019 2020-03-17 0.84 0.60
Q1 2019 2020-03-17 0.75 0.66
Q1 2018 2020-03-17 0.69 0.69
Q2 2018 2020-03-17 0.76 0.62
Q4 2018 2020-03-17 0.71 0.58

Ratings

2016-07-08 Reiterated Rating JPMorgan Chase & Co. Hold $45.00
2016-07-06 Reiterated Rating Goldman Sachs Group Inc. Buy
2016-06-13 Reiterated Rating Piper Jaffray Overweight $60.00
2016-06-13 Reiterated Rating Piper Jaffray Cos. Overweight $60.00
2016-06-06 Reiterated Rating JPMorgan Chase & Co. Neutral $45.00
2016-05-17 Upgrade Leerink Partner Market Perform to Outperform
2016-05-17 Upgrade Leerink Swann Market Perform to Outperform
2016-05-10 Reiterated Rating Credit Suisse Hold
2016-05-10 Reiterated Rating BMO Capital Markets Hold $43.00
2016-05-10 Reiterated Rating Piper Jaffray Overweight $58.00 to $60.00
2016-05-10 Reiterated Rating Credit Suisse Group AG Hold
2016-05-08 Reiterated Rating Morgan Stanley Sell
2016-05-06 Upgrade Goldman Sachs Buy to Conviction-Buy
2016-05-04 Initiated Coverage Evercore ISI Buy $51.00
2016-04-27 Reiterated Rating RBC Capital Sector Perform $40.00 to $47.00
2016-04-27 Reiterated Rating Royal Bank Of Canada Sector Perform $40.00 to $47.00
2016-04-25 Boost Price Target Credit Suisse Neutral $39.00 to $45.00
2016-04-14 Upgrade Piper Jaffray Neutral to Overweight $39.00 to $58.00
2016-03-24 Reiterated Rating Argus Hold
2016-03-21 Upgrade Leerink Partner Market Perform to Outperform
2016-02-03 Boost Price Target BMO Capital Markets Market Perform $33.00 to $38.00
2016-02-03 Boost Price Target Goldman Sachs Buy $45.00 to $46.00
2016-02-03 Reiterated Rating RBC Capital Hold $37.00 to $40.00
2016-02-03 Boost Price Target Goldman Sachs Group Inc. Buy $45.00 to $46.00
2015-11-16 Lower Price Target Piper Jaffray Overweight to Overweight $90.00 to $39.00
2015-11-13 Boost Price Target Goldman Sachs $43.00
2015-10-28 Reiterated Rating Leerink Swann Market Perform $42.00
2015-10-28 Lower Price Target Cowen and Company $74.00 to $38.00
2015-10-09 Lower Price Target BMO Capital Markets $33.00
2015-08-27 Lower Price Target Goldman Sachs $45.00
2015-08-11 Boost Price Target Barclays Overweight $45.00
2015-08-11 Boost Price Target Barclays PLC Overweight $45.00
2015-08-10 Reiterated Rating Credit Suisse Hold
2015-07-31 Downgrade S&P Equity Research Hold $42.00
2015-07-30 Downgrade Leerink Swann Outperform to Market Perform $82.00 to $40.00
2015-07-13 Reiterated Rating Deutsche Bank Hold $66.00 to $37.00
2015-07-13 Lower Price Target RBC Capital Sector Perform $74.00 to $37.00
2015-07-13 Reiterated Rating Deutsche Bank AG Hold $66.00 to $37.00
2015-07-08 Set Price Target BMO Capital Markets $36.00
2015-07-07 Downgrade BMO Capital Markets Outperform to Market Perform
2015-07-03 Set Price Target Barclays Overweight $80.00 to $43.00
2015-07-02 Reiterated Rating Barclays Overweight $80.00 to $43.00
2015-07-02 Downgrade Bank of America Buy to Neutral
2015-07-02 Downgrade Bank of America Corp. Buy to Neutral
2015-07-01 Downgrade Credit Suisse Outperform to Neutral $75.00 to $39.00
2015-06-23 Initiated Coverage Goldman Sachs Buy
2015-06-02 Reiterated Rating Deutsche Bank Hold $66.00
2015-05-23 Reiterated Rating Cowen and Company Market Perform $74.00
2015-05-19 Lower Price Target Barclays Overweight $83.00 to $80.00
2015-04-24 Lower Price Target BMO Capital Markets Outperform $84.00 to $80.00
2015-04-20 Reiterated Rating JPMorgan Chase & Co. Hold $67.00 to $65.00
2015-02-18 Lower Price Target JPMorgan Chase & Co. Neutral $68.00 to $65.00
2015-01-08 Boost Price Target RBC Capital Sector Perform $72.00 to $76.00
2015-01-05 Downgrade Morgan Stanley Equal Weight to Underweight $73.00
2014-10-17 Reiterated Rating Credit Suisse Outperform $80.00 to $77.00
2014-10-17 Reiterated Rating Barclays Overweight $88.00 to $83.00
2014-10-17 Lower Price Target RBC Capital Sector Perform $78.00 to $72.00
2014-10-13 Reiterated Rating Morgan Stanley Equal Weight $80.00 to $75.00
2014-10-06 Reiterated Rating Bank of America Buy $84.00 to $80.00
2014-10-06 Reiterated Rating ING Group Buy $84.00 to $80.00
2014-09-17 Reiterated Rating JPMorgan Chase & Co. Neutral $76.00 to $75.00
2014-09-08 Boost Price Target Piper Jaffray Overweight $85.00 to $96.00
2014-07-18 Reiterated Rating JPMorgan Chase & Co. Neutral $75.00 to $76.00
2014-07-18 Boost Price Target RBC Capital Sector Perform $76.00 to $78.00
2014-07-18 Boost Price Target Leerink Swann $83.00 to $85.00
2014-07-15 Boost Price Target Barclays Overweight $83.00 to $88.00
2014-04-28 Upgrade Ned Davis Research Neutral to Buy
2014-03-28 Boost Price Target Barclays Overweight $78.00 to $83.00
2014-03-28 Boost Price Target Sanford C. Bernstein $78.00 to $89.00
2014-03-28 Boost Price Target Cowen and Company $67.00 to $78.00
2014-03-28 Boost Price Target RBC Capital Sector Perform $73.00 to $76.00
2014-03-17 Downgrade Goldman Sachs Conviction-Buy to Buy $83.00 to $77.00
2014-01-24 Boost Price Target BMO Capital Markets Outperform $79.00
2014-01-24 Lower Price Target Deutsche Bank Hold $73.00 to $71.00
2014-01-07 Downgrade RBC Capital Outperform to Sector Perform $73.00
2013-11-18 Upgrade Credit Suisse Neutral to Outperform $73.00 to $80.00
2013-10-23 Reiterated Rating Goldman Sachs Conviction-Buy $86.00
2013-10-23 Downgrade Cowen and Company Outperform to Market Perform $77.00 to $67.00
2013-10-21 Lower Price Target BMO Capital Markets Outperform $82.00 to $77.00
2013-10-18 Downgrade Morgan Stanley Overweight to Equal Weight
2013-10-18 Downgrade Raymond James Outperform to Market Perform $80.00
2013-10-14 Reiterated Rating Citigroup Inc. Neutral $75.00 to $70.00
2013-10-04 Reiterated Rating JPMorgan Chase & Co. Hold $76.00
2013-10-04 Lower Price Target RBC Capital Outperform $77.00 to $73.00
2013-10-02 Downgrade Credit Suisse Outperform to Neutral $81.00 to $73.00
2013-09-25 Initiated Coverage JPMorgan Chase & Co. Overweight to Neutral $76.00
2013-07-19 Reiterated Barclays Overweight $76 to $82
2012-12-05 Reiterated Mizuho Neutral $72 to $68
2012-11-27 Downgrade Mizuho Buy to Neutral $72
2012-11-02 Reiterated Mizuho Buy $70 to $72
2012-09-24 Downgrade Deutsche Bank Buy to Hold $63 to $63
2012-07-19 Downgrade Standpoint Research Buy to Hold
2012-06-22 Reiterated RBC Capital Mkts Outperform $60 to $58
2012-06-01 Upgrade Standpoint Research Hold to Buy $58
2012-02-28 Reiterated UBS Buy $63 to $66
2016-07-08 Reiterated Rating JPMorgan Chase & Co. Hold $45.00
2016-07-06 Reiterated Rating Goldman Sachs Group Inc. Buy
2016-06-13 Reiterated Rating Piper Jaffray Overweight $60.00
2016-06-13 Reiterated Rating Piper Jaffray Cos. Overweight $60.00
2016-06-06 Reiterated Rating JPMorgan Chase & Co. Neutral $45.00

There is presents forecasts of rating agencies and recommendations for investors about this ticker

Major Shareholders

Name Relationship Total Shares Holding stocks
Third Point LLC 6.65%  (36001790) BAX /
Baxter Healthcare SA 2.89%  (15673981) BAX / CTIC / ONTX /
PARKINSON ROBERT L JR Chairman of the Board & CEO 0.13%  (693401) BAX /
SACCARO JAMES CVP and CFO 0.02%  (130345) BAX /
Davis Robert M Corporate Vice President 0.02%  (128146) BAX / BCR / DUK / MRK /
HANTSON LUDWIG Corporate Vice President 0.02%  (109990) ALXN / BAX /
Scharf David P. Corporate Vice President 0.02%  (109789) BAX /
Mason Jeanne K Corporate Vice President 0.02%  (97382) BAX /
ALMEIDA JOSE E Executive Officer 0.02%  (90715) ADI / BAX / COV / EMC / STT /
Eyre Brik V CVP, Hospital Products 0.01%  (81190) BAX /
HOMBACH ROBERT J. Corporate Vice President & CFO 0.01%  (63431) BAX / BMRN /
BUTEL JEAN LUC Corporate Vice President 0.01%  (62316) BAX / VAR /
Vibert Paul CVP, International 0.01%  (51283) BAX /
Accogli Giuseppe CVP, Renal 0.01%  (49918) BAX /
Schaaf Jill M CVP, Renal 0.01%  (47779) BAX /
Schabacker Marcus CVP, Chief Scientific Officer 0.01%  (35602) BAX /
Lawrence Timothy P CVP, Operations 0.01%  (34478) BAX /
GAVIN JAMES R III 0.01%  (32638) ABIO / BAX /
FOSLER GAIL D 0.01%  (32566) BAX /
Felicelli Robert CVP, Quality 0.01%  (30992) BAX /
FORSYTH JOHN D 0.01%  (28684) BAX /

Comments